Belite Bio Inc ADR

Yahoo Finance • 14 days ago

Belite Bio Announces Completion of DRAGON, a 2-Year, Phase 3 Trial of Oral Tinlarebant in the Treatment of Stargardt Disease

Tinlarebant has been granted Breakthrough Therapy, Fast Track, and Rare Pediatric Disease Designations in the U.S.; Orphan Drug Designation in the U.S., Europe, and Japan; and Pioneer Drug Designation in Japan for Stargardt diseaseLast sub... Full story

Yahoo Finance • 18 days ago

Belite Bio Announces Up to $275 Million Upsized Private Placement Financing by Leading Healthcare Investors

Transaction led by RA Capital Management with participation from Eventide Asset Management, Marshall Wace, RTW Investments, Soleus Capital and Vestal Point Capital$125 million financing upfront with up to an additional $150 million tied to... Full story

Yahoo Finance • last month

Belite Bio Q2 2025 presentation: expenses rise as clinical trials advance

Belite Bio (NASDAQ:BLTE) reported increased expenses and widening losses in its Q2 2025 financial results presentation on August 11, while highlighting progress in its late-stage clinical trials for retinal diseases. The ophthalmology-focu... Full story

Yahoo Finance • 2 months ago

Belite Bio GAAP EPS of -$0.31 beats by $0.10

* Belite Bio press release [https://seekingalpha.com/pr/20195622-belite-bio-reports-second-quarter-2025-financial-results-and-provides-a-corporate-update] (NASDAQ:BLTE [https://seekingalpha.com/symbol/BLTE]): Q2 GAAP EPS of -$0.31 beats... Full story

Yahoo Finance • 2 months ago

Belite Bio Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Tinlarebant granted Breakthrough Therapy Designation for Stargardt disease (STGD1) by the U.S. Food and Drug Administration (FDA)DRAGON trial completion expected by Q4 2025 (including a three-month follow-up period)Enrollment completed wit... Full story

Yahoo Finance • 2 months ago

Belite Bio Announces Registered Direct Offering of $15 Million

The offering was to a single large existing institutional shareholder SAN DIEGO, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc ("BLTE" or the "Company") (Nasdaq: BLTE), a clinical-stage drug development company focused on advancing... Full story

Yahoo Finance • 3 months ago

Belite Bio stock maintains Buy rating at H.C. Wainwright on trial progress

Investing.com - H.C. Wainwright has reiterated a Buy rating and $100.00 price target on Belite Bio, Inc, ADR (NASDAQ:BLTE), currently trading at $56.81 with a market cap of $1.85 billion, following the completion of enrollment in a key cli... Full story

Yahoo Finance • 3 months ago

Belite Bio Announces Completion of Enrollment in the Pivotal Global Phase 3 PHOENIX Trial Evaluating Oral Tinlarebant in Geographic Atrophy

-  500 subjects enrolled across the United States, the United Kingdom, France, Czech Republic, Switzerland, China, Taiwan, and Australia SAN DIEGO, July 02, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage drug... Full story

Yahoo Finance • 4 months ago

Belite Bio Announces FDA Granting of Breakthrough Therapy Designation for Tinlarebant for the Treatment of Stargardt Disease

Designation is based on the pivotal Phase 3 DRAGON trial interim analysis results demonstrating Tinlarebant’s efficacy and favorable safety profileTrial completion expected by Q4 2025 (including a three-month follow-up period) Tinlarebant... Full story

Yahoo Finance • 4 months ago

Deutsche Bank ADR Virtual Investor Conference: Presentations Now Available for Online Viewing

NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Depositary Receipts Virtual Investor Conference (“dbVIC”) held May 15... Full story

Yahoo Finance • 4 months ago

Belite Bio Reports First Quarter 2025 Financial Results and Provides Corporate Update

Following a pre-specified interim analysis, an independent Data Safety Monitoring Board (DSMB) recommended the pivotal Phase 3 trial (DRAGON) of Tinlarebant in adolescent Stargardt disease (STGD1) patients proceed without any modification;... Full story

Yahoo Finance • 4 months ago

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025

NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Thursday, May 15, 2025 featuring live webcast presentations from international compa... Full story

Yahoo Finance • 6 months ago

Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website

SAN DIEGO, March 17, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a San Diego based clinical stage biopharmaceutical drug development company, today announced that its annual report on Form 20-F, containing audited consolidat... Full story

Yahoo Finance • 6 months ago

Belite Bio Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update

Following a pre-specified interim analysis, the Data Safety Monitoring Board (DSMB) recommended the DRAGON trial, a pivotal Phase 3 trial in adolescent Stargardt 1 (STGD1) subjects, proceed without any modification; trial completion expect... Full story

Yahoo Finance • 7 months ago

Belite Bio to Host Webcast on March 17, 2025, to Discuss Fourth Quarter and Full Year 2024 Financial Results

SAN DIEGO, March 11, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significa... Full story

Yahoo Finance • last year

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on September 24th and 25th, 2024

Virtual Investor Conferences NEW YORK, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Tuesday, September 24 and Wednesday, September 25, fea... Full story

Yahoo Finance • 2 years ago

Belite Bio to Participate in the Benchmark Company’s Upcoming Discovery One-on-One Investor Conference

SAN DIEGO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significan... Full story

Yahoo Finance • 2 years ago

Belite Bio to Participate in the BTIG Ophthalmology Day

SAN DIEGO, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc. (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significa... Full story

Yahoo Finance • 2 years ago

Belite Bio Reports Third Quarter 2023 Operational Highlights and Financial Results

Completed enrollment in pivotal Phase 3 “DRAGON” trial for Tinlarebant in adolescent Stargardt disease (“STGD1”) with 104 subjects enrolled across 11 countries worldwide First subject dosed with Tinlarebant in pivotal global Phase 3 “PHOEN... Full story

Yahoo Finance • 2 years ago

Belite Bio to Host Webcast on November 14, 2023, to Discuss Third Quarter 2023 Financial Results

SAN DIEGO, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significan... Full story